Therefore, the PI3K pathway is a suitable target for novel anticancer therapies, and the combination ABL TKI and PI3K inhibitor therapy may prove to be an effective therapeutic strategy for eliminating CML stem cells via BCR-ABL-dependent or -independent mechanisms. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.